Compare Eli Lilly And Co (LLY) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Vanguard Growth Index Fund ETF — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Vanguard Growth Index Fund ETF trades at $91.97 (market cap $384.60B). The key difference: Eli Lilly And Co is far larger — about 2.7× Vanguard Growth Index Fund ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while Vanguard Growth Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Vanguard Growth Index Fund ETF for 47 Days on average.
| LLY | VUG | |
|---|---|---|
Market Cap | $1.04T | $384.60B |
Volume | 3,064,878 | 5,662,307 |
Sector | Health | Sector/Thematic |
52-Week High | $1.28K | $92.64 |
52-Week Low | $799.57 | $70.00 |
Typical Hold Time | 93 Days | 47 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company's weight-loss drug portfolio continues to drive exceptional performance, with Q2 2026 EPS of $8.38 beating expectations by 31%. Technical indicators show bullish moving averages while fundamentals reveal impressive 83.4% gross margins and 102.44% ROE. Recent clinical trial successes for next-generation obesity treatments position Lilly for continued market leadership.
LLY presents a compelling growth story with dominant positioning in the expanding obesity/diabetes market, though elevated valuations (P/E 39.26) and regulatory risks require monitoring. Analyst consensus remains strongly bullish with $1,350 price target representing 15% upside. The primary investment thesis centers on pipeline execution and market expansion opportunities, balanced against competitive pressures and valuation concerns.
VUG trades at $91.31, down 1.2% on the day, with a bullish technical signal supported by moving averages. The ETF maintains strong long-term performance with historical annual returns around 11-12% since inception. Recent news highlights VUG's concentration in mega-cap technology stocks like Nvidia, Apple, and Microsoft, which comprise over 36% of holdings. The fund's low 0.03% expense ratio appeals to cost-conscious investors seeking growth exposure.
VUG offers compelling long-term growth potential for investors with multi-decade horizons, though its heavy tech concentration presents both opportunity and risk. While historical performance has outpaced the broader market, current market conditions show value funds outperforming growth strategies in 2026. The ETF remains suitable for buy-and-hold investors seeking large-cap growth exposure with minimal fees.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
